NKGen Korea Appoints Four New Board Members

NKGen Korea, formerly NKMax Co., recently completed a shareholder-approved name change on November 21, 2025. On this date, NKGen Korea also announced through its official KOSDAQ disclosures the appointment of three new members to its Board of Directors: Hanhan Xu, Xuan Zhang, and Dr. June Lee each for a three-year term. Earlier, on August 14, 2025, Dr. Angie You was appointed to the NKGen Korea Board for a one-year term. You is CEO and Co-Founder of Architect Therapeutics; Xu is Managing Director, AlpineBrook Capital Group; Zhang is Operating Director, AlpineBrook Capital Group; Lee is former Chief Development Officer and COO of MyoKardia. "We welcome the addition of Dr. Angie You, Ms. Hanhan Xu, Ms. Xuan Zhang, and Dr. June Lee to the NKGen Korea Board," said Paul Song, CEO. "These appointments were made by the NKGen Korea Board, and as the majority shareholder, we fully support them. Each director brings a proven track record of building successful companies, along with deep operational and strategic expertise. Their guidance and governance will be invaluable as NKGen Korea emerges from rehabilitation and accelerates its development of NK cell therapies in Asia and lays the foundation for future commercialization. These appointments represent an exciting step forward in strengthening NKGen Korea's leadership and advancing its mission across the Asia-Pacific region."